Program at a glance
The ISOO 2022 Congress will take place from Friday, June 17 - Tuesday, June 21, 2022 in Leiden, The Netherlands. Please click on the image below for the full program at a glance. An overview of the sessions can be found below.
Sunday, June 19, 2022
08:00 a.m. - 08:45 a.m.
Johannes Vermeer and Frans van Mieris
I3 - Industry Presentation Eckert & Ziegler BEBIG - An update on Ru-106 brachytherapy and related topics
08:02 a.m. - 08:14 a.m.
Ruthenium brachytherapy or Proton beam: How to make a sound decision
Presenter:
Marina Marinkovic (The Netherlands)
08:14 a.m. - 08:26 a.m.
How MRI can help optimize the treatment of uveal melanoma
Presenter:
Jan-Willem Beenakker (The Netherlands)
08:26 a.m. - 08:38 a.m.
How I place a Ru-106 plaque just where I want it to be
Presenter:
Bertil Damato (United Kingdom/Sweden)
08:38 a.m. - 08:45 a.m.
Technical Details on Ru-106 Eye Applicators
Presenter:
Carmen Schulz (Germany)
08:00 a.m. - 09:00 a.m.
Singel walk
08:00 a.m. - 09:00 a.m.
Godfried Schalcken
Poster session Uveal Melanoma 2.1
Moderators:
Maura Di Nicola (United States), Nanda Horeweg (The Netherlands) & Hatem Krema (Canada)
Post-operative echography for optimization of radiation dosimetry in patients with posterior uveal melanoma treated with plaque brachytherapy
Presenter:
Elaine Binkley (United States)
Gene expression profile and local tumor recurrence of irradiated uveal melanomas
Presenter:
Maura Di Nicola (United States)
Oncological outcome and eye preservation in the first year of a new proton therapy center
Presenter:
Nanda Horeweg (The Netherlands)
Impact of local availability of proton therapy for uveal melanoma on visual outcome
Presenter:
Nanda Horeweg (The Netherlands)
41-gauge fine-needle aspiration biopsy for intraocular tumor
Presenter:
Min Kim (South Korea)
Laser treatment for choroidal melanoma
Presenter:
Abhilasha Maheshwari (United States)
Iris melanoma and sudden death
Presenter:
Scott Oliver (United States)
Clinical utility of preoperative dosimetry for brachytherapy in uveal melanoma
Presenter:
Scott Oliver (United States)
Telomerase gene promoter (TERT) mutation in recurrent uveal melanoma after secondary enucleation revealed by targeted next-generation sequencing
Presenter:
Brittany Perzia (United States)
Can the late effects of fractionated stereotactic radiotherapy for posterior choroidal melanoma be reduced and allow useful vision preservation without compromising metastasis-free survival? A pilot study
Presenter:
Claire Phillips (Australia)
Comparison of MRI-based and conventional measurements for proton beam therapy of uveal melanoma
Presenter:
Berit Verbist (The Netherlands)
Asymmetric loading of Iodine-125 episcleral plaques: Indications and outcomes
Presenter:
Filiberto Altomare (Canada)
Epiphora following specialised teletherapy to medially located ocular tumours
Presenter:
Umiya Harley (United Kingdom)
Accuracy of residual interfraction patient positioning in Ocular Proton Therapy (OPT)
Presenter:
Martijn Hol (The Netherlands)
Inter-observer variability in MR-based target volume delineation of uveal melanoma
Presenter:
Lisa Klaassen (The Netherlands)
3D MRI tumour measurements compared to conventional ultrasound for treatment planning of eye tumours
Presenter:
Lisa Klaassen (The Netherlands)
Biopsies of intraocular tumors - A retrospective analysis from 2017 to 2019
Presenter:
Stefan H. Kreis (Germany)
Germline genetic testing for uveal melanoma: A simplified process
Presenter:
Hatem Krema (Canada)
Demographic and clinical characterization of uveal melanoma patients in a German ophthalmic oncology reference center between 2007 and 2021
Presenter:
Mael Lever (Germany)
08:00 a.m. - 09:00 a.m.
Pieter van Slingelandt
Poster session Uveal Melanoma 2.2
Moderators:
Jan-Willem Beenakker (The Netherlands), Hung-Da Chou (Taiwan) & Michael Tang (The Netherlands)
Amelanotic melanoma presenting as tubercular granuloma
Presenter:
Vishal Raval (India)
Small choroidal melanoma presenting with submacular hemorrhage
Presenter:
Pukhraj Rishi (United States)
MR-based follow-up after brachytherapy and proton beam therapy in uveal melanoma
Presenter:
Michael Tang (The Netherlands)
Spontaneous metastasis of uveal melanoma in a mouse orthotopic xenograft model
Presenter:
Raquel Ramos (Spain)
Clinical indications for an MRI for uveal melanoma patients
Presenter:
Jan-Willem Beenakker (The Netherlands)
Using proton beam therapy without preplaced fiducial markers for choroidal melanoma: A preliminary report from a single institute in Asia
Presenter:
Hung-Da Chou (Taiwan)
How do Australian optometrists and ophthalmologists manage choroidal naevi?
Presenter:
Michele C. Madigan (Australia)
I-125 plaque radiation compared with proton radiation for treatment of uveal melanoma
Presenter:
Arman Mashayekhi (United States)
Uveal melanoma surgical approach trough endoresection: A monocentric experience
Presenter:
Cinzia Mazzini (Italy)
Long-term visual outcomes of patients with temporal uveal melanoma treated with proton beam radiotherapy
Presenter:
Sacha Nahon-Esteve (France)
Is ultrasonographic hollowness a prognostic biomarker to identify amelanotic choroidal nevi at risk of transformation into melanoma?
Presenter:
Monica Maria Pagliara (Italy)
Endoresection as primary or secondary management of choroidal melanoma
Presenter:
David Reichstein (United States)
Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 Cases
Presenter:
Carol L. Shields (United States)
Radiation retinopathy: Pilot use of long-acting intravitreal fluocinolone implant
Presenter:
Janani Singaravelu (United States)
Long term clinical outcomes with dedicated proton ocular beam and helium ion radiation for uveal melanoma patients aged 45 and younger
Presenter:
Carly Zako (United States)
Uveal melanoma patients reported outcomes (PROMS)
Presenter:
Vicktoria (vicky) Vishnevskia-Dai (Israel)
Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling
Presenter:
Basil Williams (United States)
Consensus statement for metastatic surveillance of uveal melanomas in Scotland
Presenter:
Vikas Chadha (United Kingdom)
09:00 a.m. - 10:30 a.m.
Johannes Vermeer and Frans van Mieris
S12 - Uveal melanoma, basic
Moderators:
Zelia Correa (United States), Emine Kiliç (The Netherlands), Edoardo Midena (Italy) & Alexandre Moulin (Switzerland)
09:00 a.m. - 09:07 a.m.
Trends in epidemiology of ocular melanoma
Presenter:
Emine Kiliç (The Netherlands)
09:07 a.m. - 09:14 a.m.
Germline MBD4 Mutations and predisposition to uveal melanoma
Presenter:
Anais Le Ven (France)
09:14 a.m. - 09:21 a.m.
Exploiting a human eye organoid model to understand the role of BAP1 in uveal melanoma metastasis
Presenter:
Priya Begani (United States)
09:21 a.m. - 09:28 a.m.
Cell-free tumor DNA as a target for biomarker analysis in patients with uveal melanoma (UM): Suitability for prognostic testing
Presenter:
Claudia H.d. Le Guin (Germany)
09:28 a.m. - 09:35 a.m.
In vivo liquid biopsy of uveal melanoma: An aqueous humor proteomic study
Presenter:
Edoardo Midena (Italy)
09:35 a.m. - 09:42 a.m.
Electrochemotherapy as a therapeutic radiosentitizing modality in 3D spheroids of primary uveal melanoma cell lines
Presenter:
Miltiadis Fiorentzis (Germany)
09:42 a.m. - 09:49 a.m.
A phase 1 study of percutaneous autolytic rose bengal disodium for metastatic uveal melanoma patients with hepatic metastases
Presenter:
Krysta Mcvay (United States)
09:49 a.m. - 09:56 a.m.
Prognostic significance of tumor infiltrating lymphocytes and immune checkpoint markers in uveal melanoma
Presenter:
Lata Singh (India)
09:56 a.m. - 10:03 a.m.
Direct gene expression profile prediction for uveal melanoma from digital cytopathology images via deep learning and salient image region identification
Presenter:
Zelia Correa (United States)
10:03 a.m. - 10:10 a.m.
CyberKnife vs protons: What might be the best approach to reduce complications in posterior uveal melanomas?
Presenter:
Emma Fleury (The Netherlands)
10:10 a.m. - 10:17 a.m.
Pilot clinical study of ocular prosthesis manufacture using three-dimensional (3D) printing
Presenter:
Mandeep Sagoo (United Kingdom)
10:17 a.m. - 10:24 a.m.
Medium to long-term results of Baerveldt shunt surgery for glaucoma secondary to anterior uveal melanoma treated with proton therapy
Presenter:
Ann Schalenbourg (Switzerland)
10:30 a.m. - 11:00 a.m.
Coffee break
10:30 a.m. - 11:00 a.m.
Godfried Schalcken
Poster session Uveal Melanoma 2.1 - cont.
Moderators:
Maura Di Nicola (United States), Nanda Horeweg (The Netherlands) & Hatem Krema (Canada)
Post-operative echography for optimization of radiation dosimetry in patients with posterior uveal melanoma treated with plaque brachytherapy
Presenter:
Elaine Binkley (United States)
Gene expression profile and local tumor recurrence of irradiated uveal melanomas
Presenter:
Maura Di Nicola (United States)
Oncological outcome and eye preservation in the first year of a new proton therapy center
Presenter:
Nanda Horeweg (The Netherlands)
Impact of local availability of proton therapy for uveal melanoma on visual outcome
Presenter:
Nanda Horeweg (The Netherlands)
41-gauge fine-needle aspiration biopsy for intraocular tumor
Presenter:
Min Kim (South Korea)
Laser treatment for choroidal melanoma
Presenter:
Abhilasha Maheshwari (United States)
Iris melanoma and sudden death
Presenter:
Scott Oliver (United States)
Clinical utility of preoperative dosimetry for brachytherapy in uveal melanoma
Presenter:
Scott Oliver (United States)
Telomerase gene promoter (TERT) mutation in recurrent uveal melanoma after secondary enucleation revealed by targeted next-generation sequencing
Presenter:
Brittany Perzia (United States)
Can the late effects of fractionated stereotactic radiotherapy for posterior choroidal melanoma be reduced and allow useful vision preservation without compromising metastasis-free survival? A pilot study
Presenter:
Claire Phillips (Australia)
Comparison of MRI-based and conventional measurements for proton beam therapy of uveal melanoma
Presenter:
Berit Verbist (The Netherlands)
Asymmetric loading of Iodine-125 episcleral plaques: Indications and outcomes
Presenter:
Filiberto Altomare (Canada)
Epiphora following specialised teletherapy to medially located ocular tumours
Presenter:
Umiya Harley (United Kingdom)
Accuracy of residual interfraction patient positioning in Ocular Proton Therapy (OPT)
Presenter:
Martijn Hol (The Netherlands)
Inter-observer variability in MR-based target volume delineation of uveal melanoma
Presenter:
Lisa Klaassen (The Netherlands)
3D MRI tumour measurements compared to conventional ultrasound for treatment planning of eye tumours
Presenter:
Lisa Klaassen (The Netherlands)
Biopsies of intraocular tumors - A retrospective analysis from 2017 to 2019
Presenter:
Stefan H. Kreis (Germany)
Germline genetic testing for uveal melanoma: A simplified process
Presenter:
Hatem Krema (Canada)
Demographic and clinical characterization of uveal melanoma patients in a German ophthalmic oncology reference center between 2007 and 2021
Presenter:
Mael Lever (Germany)
10:30 a.m. - 11:00 a.m.
Pieter van Slingelandt
Poster session Uveal Melanoma 2.2 - cont.
Moderators:
Jan-Willem Beenakker (The Netherlands), Hung-Da Chou (Taiwan) & Michael Tang (The Netherlands)
Amelanotic melanoma presenting as tubercular granuloma
Presenter:
Vishal Raval (India)
Small choroidal melanoma presenting with submacular hemorrhage
Presenter:
Pukhraj Rishi (United States)
MR-based follow-up after brachytherapy and proton beam therapy in uveal melanoma
Presenter:
Michael Tang (The Netherlands)
Spontaneous metastasis of uveal melanoma in a mouse orthotopic xenograft model
Presenter:
Raquel Ramos (Spain)
Clinical indications for an MRI for uveal melanoma patients
Presenter:
Jan-Willem Beenakker (The Netherlands)
Using proton beam therapy without preplaced fiducial markers for choroidal melanoma: A preliminary report from a single institute in Asia
Presenter:
Hung-Da Chou (Taiwan)
How do Australian optometrists and ophthalmologists manage choroidal naevi?
Presenter:
Michele C. Madigan (Australia)
I-125 plaque radiation compared with proton radiation for treatment of uveal melanoma
Presenter:
Arman Mashayekhi (United States)
Uveal melanoma surgical approach trough endoresection: A monocentric experience
Presenter:
Cinzia Mazzini (Italy)
Long-term visual outcomes of patients with temporal uveal melanoma treated with proton beam radiotherapy
Presenter:
Sacha Nahon-Esteve (France)
Is ultrasonographic hollowness a prognostic biomarker to identify amelanotic choroidal nevi at risk of transformation into melanoma?
Presenter:
Monica Maria Pagliara (Italy)
Endoresection as primary or secondary management of choroidal melanoma
Presenter:
David Reichstein (United States)
Conditional survival of uveal melanoma using The Cancer Genome Atlas (TCGA) classification (Simplified Version) in 1001 Cases
Presenter:
Carol L. Shields (United States)
Radiation retinopathy: Pilot use of long-acting intravitreal fluocinolone implant
Presenter:
Janani Singaravelu (United States)
Long term clinical outcomes with dedicated proton ocular beam and helium ion radiation for uveal melanoma patients aged 45 and younger
Presenter:
Carly Zako (United States)
Uveal melanoma patients reported outcomes (PROMS)
Presenter:
Vicktoria (vicky) Vishnevskia-Dai (Israel)
Uveal melanoma patient attitudes towards prognostic testing using gene expression profiling
Presenter:
Basil Williams (United States)
Consensus statement for metastatic surveillance of uveal melanomas in Scotland
Presenter:
Vikas Chadha (United Kingdom)
11:00 a.m. - 12:30 p.m.
Johannes Vermeer and Frans van Mieris
S13 Uveal Melanoma: Clinic and Cases
Moderators:
Lauren Dalvin (United States), Marina Marinkovic (The Netherlands), Mandeep Sagoo (United Kingdom) & Ann Schalenbourg (Switzerland)
11:00 a.m. - 11:08 a.m.
MR imaging characteristics of uveal melanoma with histopathological validation
Presenter:
Teresa Ferreira (The Netherlands)
11:08 a.m. - 11:16 a.m.
Ultrasound guidance of plaque placement for choroidal melanoma
Presenter:
Brian Marr (United States)
11:16 a.m. - 11:24 a.m.
Prognostic biopsies in small choroidal melanomas
Presenter:
Rumana Hussain (United Kingdom)
11:24 a.m. - 11:32 a.m.
A phase 2 trial of a first in class targeted therapy for choroidal melanoma via suprachoroidal (SC) administration
Presenter:
Ivana Kim (United States)
11:32 a.m. - 11:40 a.m.
Transscleral resection in large uveal melanoma
Presenter:
Nikos Bechrakis (Germany)
11:40 a.m. - 11:48 a.m.
Survival after proton therapy for patients with recurrent uveal melanoma
Presenter:
Evangelos Gragoudas (United States)
11:48 a.m. - 11:51 a.m.
Association of plasma circulating tumor DNA with diagnosis of metastatic uveal melanoma
Presenter:
Jasmine Francis (United States)
11:51 a.m. - 11:54 a.m.
Bilateral nevus of Ota
Presenter:
Ana Marisa Castello Branco (Brazil)
11:54 a.m. - 11:57 a.m.
Necrotic eruption of an untreated, inflammatory choroidal melanoma
Presenter:
Andrew Stacey (United States)
11:57 a.m. - 12:00 p.m.
A slithery coincidence?
Presenter:
Prithvi Mruthyunjaya (United States)
12:00 p.m. - 12:03 p.m.
Uveal melanoma extrascleral orbital invasions - Report of three cases in 19 years
Presenter:
Vincenzina Mazzeo (Italy)
12:03 p.m. - 12:06 p.m.
Chronic exudative retinal detachment with underlying choroidal mass
Presenter:
Lauren Dalvin (United States)
12:06 p.m. - 12:09 p.m.
To see or not to see, that is the question
Presenter:
Sara Lally (United States)
12:09 p.m. - 12:12 p.m.
Clinical phenotype of patient with germline MBD4 pathogenic alteration: Monosomy 3 uveal melanoma with long survival
Presenter:
Colleen M. Cebulla (United States)
12:12 p.m. - 12:20 p.m.
Vitreous proteomics by mass spectrometry correlates with gene expression profile of uveal melanoma
Presenter:
Prithvi Mruthyunjaya (United States)
12:30 p.m. - 01:15 p.m.
Johannes Vermeer and Frans van Mieris
Industry Presentation AURA - New Developments in AU-011, an Investigational Virus-Like Drug Conjugate (VDC) for treatment of Ocular Cancer and Metastatic Disease
12:30 p.m. - 12:35 p.m.
Introduction
Presenter:
Elisabet de Los Pinos (United States)
12:36 p.m. - 12:45 p.m.
AU-011 Overview and Update on Choroidal Metastasis
Presenter:
Cadmus Rich (United States)
12:46 p.m. - 12:55 p.m.
Clinical Development of AU-011
Presenter:
Abhijit Narvekar (United States)
12:56 p.m. - 01:05 p.m.
AU-011 in combination with immune checkpoint inhibitors for the treatment of primary tumors and distant metastasis
Presenter:
Ruben Huis In 't Veld (The Netherlands)
01:06 p.m. - 01:15 p.m.
Discussion
Presenter:
Cadmus Rich (United States)
12:30 p.m. - 01:40 p.m.
Lunch
12:30 p.m. - 01:40 p.m.
Jan Steen
Poster session Uveal Melanoma 3.1
Moderators:
Maria Chiara Gelmi (The Netherlands), Rosaria Gangemi (Italy) & Dan S. Gombos (United States)
Metastatic risk factors associated with Class 1A uveal melanoma patients
Presenter:
Alexej Ballhausen (United States)
Choroidal melanoma tumor profile and treatment pattern for newly diagnosed patients in Brazil
Presenter:
Arthur Fernandes (Brazil)
New molecular target therapies for uveal melanoma
Presenter:
Rosaria Gangemi (Italy)
Plaque brachytherapy for the treatment of uveal melanoma: Our strategies and results - The experience of University of Pisa
Presenter:
Federica Genovesi Ebert (Italy)
Stereotactic radiosurgery, a really promise in the management of selected uveal melanoma
Presenter:
Federica Genovesi Ebert (Italy)
Prediction of metastatic risk using GEP, PRAME, COMS, and AJCC uveal melanoma
Presenter:
Scott Oliver (United States)
12:30 p.m. - 01:40 p.m.
Godfried Schalcken
Poster session Uveal Melanoma 3.2
Moderators:
Colleen M. Cebulla (United States), Maya Eiger-Moscovich (Israel) & Vincent Sun (Canada)
In vitro results of a novel virus like drug conjugate targeted therapy in uveal melanoma suggest immunostimulatory capacity
Presenter:
Ma Sen (The Netherlands)
Very long-term outcomes of Anti-VEGF therapy for radiation maculopathy after ophthalmic brachytherapy
Presenter:
Puneet Jain (India)
BAP1 immunohistochemistry in post-brachytherapy uveal melanoma
Presenter:
Maya Eiger-Moscovich (Israel)
A novel approach to estimating choroidal lesion thickness using 2D ultra-widefield optomap images
Presenter:
Michael Yu (United States)
De novo choroidal melanoma
Presenter:
Emily Zabor (United States)
Chandelier-assisted brachytherapy for uveal melanoma
Presenter:
Colleen M. Cebulla (United States)
Proton beam therapy for uveal melanomas - When do we see a response?
Presenter:
Matthew Gillam (United Kingdom)
12:30 p.m. - 01:40 p.m.
Pieter van Slingelandt
Poster session Uveal Melanoma 3.3
Moderators:
Niels Brouwer (The Netherlands), Michael Heiferman (United States) & Aqsa Saleem (Canada)
Loss of cilia in uveal melanoma: Implications for diagnosis
Presenter:
Michael Heiferman (United States)
Preliminary results of uveal melanoma treated with iodine-125 plaques: Analysis of disease control and visual outcomes with 63 Gy to the target volume
Presenter:
Wajiha Kheir (Lebanon)
Evaluation of radiation maculopathy after treatment of choroidal melanoma with ruthenium-106 using optical coherence tomography angiography
Presenter:
Hamid Riazi Esfahani (Iran)
Strabismus post plaque brachytherapy
Presenter:
Aqsa Saleem (Canada)
BAP1 immunostain status in intraocular biopsy specimens for uveal melanoma correlates with other prognostic markers
Presenter:
Diva Salomao (United States)
Uveal melanoma inpatient with oculo-dermal nevus of Ota (clinical case)
Presenter:
Alua Aubakirova (Kazakhstan)
01:40 p.m. - 02:00 p.m.
Johannes Vermeer and Frans van Mieris
S14 Stallard Lecture
01:40 p.m. - 01:45 p.m.
Introduction to Prof Kivela, Stallard lecturer
Presenter:
Dan S. Gombos (United States)
01:45 p.m. - 02:00 p.m.
Stallard Lecture
Presenter:
Tero T. Kivelä (Finland)
02:00 p.m. - 03:30 p.m.
Johannes Vermeer and Frans van Mieris
S15 Uveal Melanoma - Basic and Clinical approaches to Uveal Melanoma Metastases
Moderators:
Richard Carvajal (United States), Sapna Patel (United States), Alison Skalet (United States) & Serdar Yavuzyigitoglu (The Netherlands)
02:00 p.m. - 02:08 p.m.
The role of MET inhibition on the efficacy of CDK4/6 inhibitors in metastatic uveal melanoma
Presenter:
Mizue Terai (United States)
02:08 p.m. - 02:16 p.m.
A novel virus like drug conjugate in combination with immune checkpoint inhibitors for the treatment of primary choroidal tumors and distant metastasis
Presenter:
Ruben Huis In 't Veld (The Netherlands)
02:16 p.m. - 02:24 p.m.
Chimeric antigens in immunotargeting of G-alpha mutated uveal melanoma
Presenter:
Vitali Alexeev (United States)
02:24 p.m. - 02:32 p.m.
Uveal melanoma-derived exosomes contribute to promote the pre-metastatic niche in the liver by reprograming the hepatic stellate cells
Presenter:
Raquel Ramos (Spain)
02:32 p.m. - 02:40 p.m.
Development and utilization of hepatic metastasis mouse models in uveal melanoma
Presenter:
Takami Sato (United States)
02:40 p.m. - 02:48 p.m.
Circulating hybrid cells as a novel prognostic biomarker in uveal melanoma
Presenter:
Alison Skalet (United States)
02:48 p.m. - 02:56 p.m.
Testing ruthenium-based photoactivated chemotherapy on tumor-bearing mice models as a new treatment for uveal melanoma
Presenter:
Ludovic Bretin (The Netherlands)
02:56 p.m. - 03:04 p.m.
Clinical and tumor characteristics of patients with metastatic uveal melanoma (mUM) who develop brain metastases (BM)
Presenter:
Alexander Z. Wei (United States)
03:04 p.m. - 03:12 p.m.
Hepatic miliary metastases in patients with uveal melanoma
Presenter:
Serdar Yavuzyigitoglu (The Netherlands)
03:12 p.m. - 03:20 p.m.
Intermittent MEK inhibition for the treatment of Metastatic Uveal Melanoma (MUM)
Presenter:
Richard Carvajal (United States)
03:20 p.m. - 03:23 p.m.
Metabolic complete responses (mCR) in metastatic uveal melanoma (mUM) patients treated with image-guided injection (IGI) of PV-10
Presenter:
Sapna Patel (United States)
03:23 p.m. - 03:31 p.m.
Optical density ratio of subretinal fluid in choroidal melanoma versus choroidal naevus
Presenter:
Alexandre Matet (France)
03:30 p.m. - 04:00 p.m.
Coffee break
03:30 p.m. - 04:00 p.m.
Jan Steen
Poster session Uveal Melanoma 3.1 - cont.
Moderators:
Maria Chiara Gelmi (The Netherlands), Rosaria Gangemi (Italy) & Dan S. Gombos (United States)
Metastatic risk factors associated with Class 1A uveal melanoma patients
Presenter:
Alexej Ballhausen (United States)
Choroidal melanoma tumor profile and treatment pattern for newly diagnosed patients in Brazil
Presenter:
Arthur Fernandes (Brazil)
New molecular target therapies for uveal melanoma
Presenter:
Rosaria Gangemi (Italy)
Plaque brachytherapy for the treatment of uveal melanoma: Our strategies and results - The experience of University of Pisa
Presenter:
Federica Genovesi Ebert (Italy)
Stereotactic radiosurgery, a really promise in the management of selected uveal melanoma
Presenter:
Federica Genovesi Ebert (Italy)
Prediction of metastatic risk using GEP, PRAME, COMS, and AJCC uveal melanoma
Presenter:
Scott Oliver (United States)
03:30 p.m. - 04:00 p.m.
Godfried Schalcken
Poster session Uveal Melanoma 3.2 - cont.
Moderators:
Colleen M. Cebulla (United States), Maya Eiger-Moscovich (Israel) & Vincent Sun (Canada)
In vitro results of a novel virus like drug conjugate targeted therapy in uveal melanoma suggest immunostimulatory capacity
Presenter:
Ma Sen (The Netherlands)
Very long-term outcomes of Anti-VEGF therapy for radiation maculopathy after ophthalmic brachytherapy
Presenter:
Puneet Jain (India)
BAP1 immunohistochemistry in post-brachytherapy uveal melanoma
Presenter:
Maya Eiger-Moscovich (Israel)
A novel approach to estimating choroidal lesion thickness using 2D ultra-widefield optomap images
Presenter:
Michael Yu (United States)
De novo choroidal melanoma
Presenter:
Emily Zabor (United States)
Chandelier-assisted brachytherapy for uveal melanoma
Presenter:
Colleen M. Cebulla (United States)
Proton beam therapy for uveal melanomas - When do we see a response?
Presenter:
Matthew Gillam (United Kingdom)
03:30 p.m. - 04:00 p.m.
Pieter van Slingelandt
Poster session Uveal Melanoma 3.3 - cont.
Moderators:
Niels Brouwer (The Netherlands), Michael Heiferman (United States) & Aqsa Saleem (Canada)
Loss of cilia in uveal melanoma: Implications for diagnosis
Presenter:
Michael Heiferman (United States)
Preliminary results of uveal melanoma treated with iodine-125 plaques: Analysis of disease control and visual outcomes with 63 Gy to the target volume
Presenter:
Wajiha Kheir (Lebanon)
Evaluation of radiation maculopathy after treatment of choroidal melanoma with ruthenium-106 using optical coherence tomography angiography
Presenter:
Hamid Riazi Esfahani (Iran)
Strabismus post plaque brachytherapy
Presenter:
Aqsa Saleem (Canada)
BAP1 immunostain status in intraocular biopsy specimens for uveal melanoma correlates with other prognostic markers
Presenter:
Diva Salomao (United States)
Uveal melanoma inpatient with oculo-dermal nevus of Ota (clinical case)
Presenter:
Alua Aubakirova (Kazakhstan)
04:00 p.m. - 05:00 p.m.
Johannes Vermeer and Frans van Mieris
S16 ISOO Business Meeting
05:00 p.m. - 07:00 p.m.
Guided Tour through Historial Leiden
07:00 p.m. - 10:00 p.m.
BBQ dinner beach pavilion 'Het Strand'